- Home
- BLFS vs SGP Comparison
BLFS vs SGP Comparison
Compare BLFS & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLFS | SGP |
|---|---|---|
| Founded | 1987 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.5M | 932.9M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLFS | SGP |
|---|---|---|
| Price | $24.28 | $20.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $32.00 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 485.2K | 48.7K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.27 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $96,214,000.00 | N/A |
| Revenue This Year | $19.73 | N/A |
| Revenue Next Year | $17.82 | N/A |
| P/E Ratio | $1,208.50 | ★ N/A |
| Revenue Growth | ★ 16.97 | N/A |
| 52 Week Low | $17.86 | $19.46 |
| 52 Week High | $29.57 | $30.56 |
Technical Indicators
Market Signals| Indicator | BLFS | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 63.86 | 33.40 |
| Support Level | $23.74 | N/A |
| Resistance Level | $26.55 | $26.29 |
| Average True Range (ATR) | 1.18 | 1.65 |
| MACD | 0.25 | -0.35 |
| Stochastic Oscillator | 83.54 | 10.45 |
Price Performance
Historical ComparisonAbout BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About SGP SpyGlass Pharma Inc. Common Stock
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.